WASHINGTON — President Biden’s presumed pick to lead the National Institutes of Health, Monica Bertagnolli, will face a slew of questions on the multibillion-dollar agency’s spending and oversight in her upcoming confirmation battle.
This week, though, she won’t face what otherwise would have been Congress’s first round. A source close to the top cancer official, who announced her own cancer diagnosis last December, said she had to drop out of a scheduled Senate Appropriations Committee hearing Thursday because of previously scheduled routine cancer treatment, though she remains healthy.
The National Cancer Institute’s second-in-command, Douglas Lowy, will testify instead, alongside acting NIH director Lawrence Tabak and other senior NIH officials.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect